in control versus Tg(hs:miR-101a-sp) hearts in Figure 4J of Development 2015
—differences in (1) the amount of scarring, as represented by comparing AFOG staining in control and Tg(hs:miR-101a-sp) and Tg(hs:miR-133a1-pre) hearts exposed to long term heat therapy in Figures 5A, 5B and 5C, or Tropomyosin staining in Figures 5D, 5E, and 5F; and (2) the quantification of the scarring indices, tropomyosin expression, and injury area in Figures 5G, 5H, and 5I of Development 2015
—increased Fosab expression in Tg(hs:miR-101a-sp) ventricles relative to controls in Figures 6A and 6B, RNA in situ hybridization studies in control and regenerating hearts detecting miR-101a expression in Figures 6C, 6D, 6E, and 6F, and Fosab expression in Figures 6G, 6H, 6I, 6J, 6K, 7C, 7D, and 7E of Development 2015
—images reporting significant differences in Dscd expression, cardiomyocyte proliferation, collagen and fibrin staining, and scar tissue removal in ventricles from zebrafish treated with Ina-Let-7, as compared to scrambled control, to support the importality of miR-101a in scar tissue removal/ventricular regeneration in Figures 6H, 6J, 6L, 7C, 7D, and 7E of Development 2015
• reporting research methods and statistics that were not performed in the following experimental results:
—PCR data in the graph represented in Figure 2B of PNAS 2018 draft, iScience 2018 draft, and iScience 2019, by representing the data from two (2) remote PCR experiments as being from the same experiment
—PCR data in the graph represented in Figure 2B of iScience Correction by reusing and relabeling a graph containing data that were the result of different experimental conditions (exposure to heat shock), to include scrambled control data
—control data and statistical differences between control and experimental data represented in PNAS 2018 draft, iScience 2018 draft, iScience 2019, and iScience Correction, by falsely reporting the use of both antisense scrambled and LNA oligonucleotides that were designed and administered to adult animals via intraperitoneal injection at 10ug/g body weight
—representing the “n” of one biological replicate or one experiment as being multiple independent samples or experiments in iScience 2019 and iScience Correction
—control data and statistical differences between control and experimental data and the reported methods in Development 2015, concluding that miR-101a controls both CM proliferation and scar tissue removal, by falsely reporting the use of LNA oligonucleotides to modulate miR-101 activity in vivo to elucidate its contributions during adult heart regeneration
Dr. Yin entered into a Voluntary Agreement (Agreement) and voluntarily agreed to the following:
(1) Respondent agreed to have his research supervised for a period of two (2) years beginning on August 2, 2021. Respondent agreed that prior to submission of an application for PHS support for a research project on which Respondent’s participation is proposed and prior to Respondent’s participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of Respondent’s duties is submitted to ORI for approval. The supervision plan must be designed to ensure the scientific integrity of Respondent’s research contribution. Respondent agreed that he shall not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI. Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan.
(2) The requirements for Respondent’s supervision plan are as follows:
   i. A committee of 2–3 senior faculty members at the institution who are familiar with Respondent’s field of research, but not including Respondent’s supervisor or collaborators, will provide oversight and guidance for a period of two (2) years from the effective date of the Agreement. The committee will review primary data from Respondent’s laboratory on a quarterly basis and submit a report to ORI at six (6) month intervals setting forth the committee meeting dates and Respondent’s compliance with appropriate research standards and confirming the integrity of Respondent’s research.
   ii. The committee will conduct an advance review of any PHS grant applications (including supplements, resubmissions, etc.), manuscripts reporting PHS-funded research submitted for publication, and abstracts. The committee will also include a discussion with Respondent of the primary data represented in those documents and will include a certification to ORI that the data presented in the proposed application/publication is supported by the research.
(3) Respondent agreed that for a period of two (2) years beginning on August 2, 2021, any institution employing him shall submit, in conjunction with each application of PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript or abstract.
(4) If no supervisory plan is provided to ORI, Respondent agreed to provide certification to ORI at the conclusion of the supervision period that he has not engaged in, applied for, or had his name included on any application, proposal, or other request for PHS funds without prior notification to ORI.
(5) Respondent agreed to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of two (2) years, beginning on August 2, 2021.
(6) As a condition of the Agreement, Respondent will request that the following papers be retracted in accordance with 42 CFR 93.407(a)(1) and § 93.411(b):
   • Development 2015 Dec 1;142(23):4026–37
   • iScience 2019 May 31;15:1–15
   • iScience 2019 Jul 26;17:225–29
   • Wanda K. Jones, Acting Director, Office of Research Integrity, Office of the Assistant Secretary for Health.
   • [FR Doc. 2021–17777 Filed 8–18–21; 8:45 am]
   • DEPARTMENT OF HEALTH AND HUMAN SERVICES
   • National Institutes of Health
   • National Cancer Institute; Notice of Meeting
   • Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Cancer Institute Clinical Trials and Translational Research Advisory Committee.
   • The meeting will be held as a virtual meeting and is open to the public. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Environmental Health Sciences; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Advisory Environmental Health Sciences Council, September 13, 2021, 11:00 a.m. to September 14, 2021, 04:45 p.m., National Institute of Environmental Health Science, Durham, NC 27709 which was published in the Federal Register on August 16, 2021, FR Doc 2021-17410, 86 FR 45742.

This notice is being amended to change the meeting date from September 13–14, 2021 to September 13, 2021. The start time for open session is also amended and will now start at 11:45 a.m. and adjourn at 5:15 p.m. The meeting is partially closed to the public.

Dated: August 16, 2021.

David Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021-17819 Filed 8–18–21; 8:45 am]
BILLING CODE 4140–01–P